Form 4: Integra LifeSciences Director Christian S. Schade Reports Significant Stock Transactions
SEC Form 4 Filing
Director Christian S. Schade reports acquisition of Integra LifeSciences Holdings Corp stock through non-open market transactions.
Summary
- On May 9, 2025, Christian S. Schade, a director of Integra LifeSciences Holdings Corp, reported acquiring 6,939 shares of Common Stock through a non-open market transaction.
- Additionally, Schade acquired 19,592 shares of Common Stock through another non-open market transaction on the same day.
- Following these transactions, Schade beneficially owns 90,034 shares of Integra LifeSciences Holdings Corp.
- The transactions were reported on a Form 4 filing with the SEC.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. These transactions can be for a variety of reasons, including compensation, portfolio diversification, or personal financial planning.
Key Dates
| Date | Description |
|---|---|
| 05/09/2025 | Date of stock transactions (acquisition of 6,939 and 19,592 shares). |
| 05/13/2025 | Date of signature on the Form 4 filing. |
Keywords
Form 4, Beneficial Ownership, Integra LifeSciences, IART, Director, Stock Acquisition, SEC Filing, Christian S. Schade
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.